MLH1 Deficiency Down-Regulates TLR4 Expression in Sporadic Colorectal Cancer

Patients with mismatch repair (MMR)-deficient colorectal cancer (CRC) have a more favorable prognosis than patients with tumors with intact MMR. In order to obtain further insights on the reasons for this different outcome, we investigated the interplay between MMR genes and TLR4/MyD88 signaling. Th...

Full description

Bibliographic Details
Main Authors: Melania Scarpa, Cesare Ruffolo, Andromachi Kotsafti, Fabio Canal, Francesca Erroi, Silvia Basato, Lucia Dall’Agnese, Alain Fiorot, Anna Pozza, Paola Brun, Nicolò Bassi, Angelo Dei Tos, Carlo Castoro, Ignazio Castagliuolo, Marco Scarpa
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-05-01
Series:Frontiers in Molecular Biosciences
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fmolb.2021.624873/full
id doaj-94c9746dbb8e4a5a9a773b2f48d63bce
record_format Article
spelling doaj-94c9746dbb8e4a5a9a773b2f48d63bce2021-05-07T13:51:23ZengFrontiers Media S.A.Frontiers in Molecular Biosciences2296-889X2021-05-01810.3389/fmolb.2021.624873624873MLH1 Deficiency Down-Regulates TLR4 Expression in Sporadic Colorectal CancerMelania Scarpa0Cesare Ruffolo1Andromachi Kotsafti2Fabio Canal3Francesca Erroi4Silvia Basato5Lucia Dall’Agnese6Alain Fiorot7Anna Pozza8Paola Brun9Nicolò Bassi10Angelo Dei Tos11Carlo Castoro12Ignazio Castagliuolo13Marco Scarpa14Laboratory of Advanced Translational Research, Veneto Institute of Oncology IOV-IRCCS, Padua, ItalyClinica Chirurgica I, Azienda Ospedaliera di Padova, Padua, ItalyLaboratory of Advanced Translational Research, Veneto Institute of Oncology IOV-IRCCS, Padua, ItalyPathology Unit, Treviso Regional Hospital, Treviso, ItalyDepartment of Surgery, Oncology and Gastroenterology DISCOG, University of Padua, Padua, ItalyDepartment of Surgery, Oncology and Gastroenterology DISCOG, University of Padua, Padua, ItalyDepartment of Surgery, Oncology and Gastroenterology DISCOG, University of Padua, Padua, ItalyDepartment of Surgery, Oncology and Gastroenterology DISCOG, University of Padua, Padua, ItalyDepartment of Surgery, Oncology and Gastroenterology DISCOG, University of Padua, Padua, ItalyDepartment of Molecular Medicine DMM, University of Padua, Padua, ItalyDepartment of Surgery, Oncology and Gastroenterology DISCOG, University of Padua, Padua, ItalyPathology Unit, Treviso Regional Hospital, Treviso, ItalyOncological Surgery Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, ItalyDepartment of Molecular Medicine DMM, University of Padua, Padua, ItalyClinica Chirurgica I, Azienda Ospedaliera di Padova, Padua, ItalyPatients with mismatch repair (MMR)-deficient colorectal cancer (CRC) have a more favorable prognosis than patients with tumors with intact MMR. In order to obtain further insights on the reasons for this different outcome, we investigated the interplay between MMR genes and TLR4/MyD88 signaling. The cancer genome atlas (TCGA) databases were selected to predict the differential expression of TLR4 in colon cancer and its correlation with MMR genes. Moreover, the expression of MMR genes and TLR4 was evaluated by immunohistochemistry in 113 CRC samples and a cohort of 63 patients was used to assess TLR4 mRNA expression and MLH1 epigenetic silencing status. In vitro, the effect of MLH1 knockdown on TLR4 expression was quantified by Real Time PCR. TLR4 expression resulted dependent on MMR status and directly correlated to MLH1 expression. In vitro, MLH1 silencing decreased TLR4 expression. These observations may reflect the better prognosis and the chemoresistance of patients with CRC and MMR defects.https://www.frontiersin.org/articles/10.3389/fmolb.2021.624873/fullcolorectal cancerTLR4MLH1mismatchinnate immunity
collection DOAJ
language English
format Article
sources DOAJ
author Melania Scarpa
Cesare Ruffolo
Andromachi Kotsafti
Fabio Canal
Francesca Erroi
Silvia Basato
Lucia Dall’Agnese
Alain Fiorot
Anna Pozza
Paola Brun
Nicolò Bassi
Angelo Dei Tos
Carlo Castoro
Ignazio Castagliuolo
Marco Scarpa
spellingShingle Melania Scarpa
Cesare Ruffolo
Andromachi Kotsafti
Fabio Canal
Francesca Erroi
Silvia Basato
Lucia Dall’Agnese
Alain Fiorot
Anna Pozza
Paola Brun
Nicolò Bassi
Angelo Dei Tos
Carlo Castoro
Ignazio Castagliuolo
Marco Scarpa
MLH1 Deficiency Down-Regulates TLR4 Expression in Sporadic Colorectal Cancer
Frontiers in Molecular Biosciences
colorectal cancer
TLR4
MLH1
mismatch
innate immunity
author_facet Melania Scarpa
Cesare Ruffolo
Andromachi Kotsafti
Fabio Canal
Francesca Erroi
Silvia Basato
Lucia Dall’Agnese
Alain Fiorot
Anna Pozza
Paola Brun
Nicolò Bassi
Angelo Dei Tos
Carlo Castoro
Ignazio Castagliuolo
Marco Scarpa
author_sort Melania Scarpa
title MLH1 Deficiency Down-Regulates TLR4 Expression in Sporadic Colorectal Cancer
title_short MLH1 Deficiency Down-Regulates TLR4 Expression in Sporadic Colorectal Cancer
title_full MLH1 Deficiency Down-Regulates TLR4 Expression in Sporadic Colorectal Cancer
title_fullStr MLH1 Deficiency Down-Regulates TLR4 Expression in Sporadic Colorectal Cancer
title_full_unstemmed MLH1 Deficiency Down-Regulates TLR4 Expression in Sporadic Colorectal Cancer
title_sort mlh1 deficiency down-regulates tlr4 expression in sporadic colorectal cancer
publisher Frontiers Media S.A.
series Frontiers in Molecular Biosciences
issn 2296-889X
publishDate 2021-05-01
description Patients with mismatch repair (MMR)-deficient colorectal cancer (CRC) have a more favorable prognosis than patients with tumors with intact MMR. In order to obtain further insights on the reasons for this different outcome, we investigated the interplay between MMR genes and TLR4/MyD88 signaling. The cancer genome atlas (TCGA) databases were selected to predict the differential expression of TLR4 in colon cancer and its correlation with MMR genes. Moreover, the expression of MMR genes and TLR4 was evaluated by immunohistochemistry in 113 CRC samples and a cohort of 63 patients was used to assess TLR4 mRNA expression and MLH1 epigenetic silencing status. In vitro, the effect of MLH1 knockdown on TLR4 expression was quantified by Real Time PCR. TLR4 expression resulted dependent on MMR status and directly correlated to MLH1 expression. In vitro, MLH1 silencing decreased TLR4 expression. These observations may reflect the better prognosis and the chemoresistance of patients with CRC and MMR defects.
topic colorectal cancer
TLR4
MLH1
mismatch
innate immunity
url https://www.frontiersin.org/articles/10.3389/fmolb.2021.624873/full
work_keys_str_mv AT melaniascarpa mlh1deficiencydownregulatestlr4expressioninsporadiccolorectalcancer
AT cesareruffolo mlh1deficiencydownregulatestlr4expressioninsporadiccolorectalcancer
AT andromachikotsafti mlh1deficiencydownregulatestlr4expressioninsporadiccolorectalcancer
AT fabiocanal mlh1deficiencydownregulatestlr4expressioninsporadiccolorectalcancer
AT francescaerroi mlh1deficiencydownregulatestlr4expressioninsporadiccolorectalcancer
AT silviabasato mlh1deficiencydownregulatestlr4expressioninsporadiccolorectalcancer
AT luciadallagnese mlh1deficiencydownregulatestlr4expressioninsporadiccolorectalcancer
AT alainfiorot mlh1deficiencydownregulatestlr4expressioninsporadiccolorectalcancer
AT annapozza mlh1deficiencydownregulatestlr4expressioninsporadiccolorectalcancer
AT paolabrun mlh1deficiencydownregulatestlr4expressioninsporadiccolorectalcancer
AT nicolobassi mlh1deficiencydownregulatestlr4expressioninsporadiccolorectalcancer
AT angelodeitos mlh1deficiencydownregulatestlr4expressioninsporadiccolorectalcancer
AT carlocastoro mlh1deficiencydownregulatestlr4expressioninsporadiccolorectalcancer
AT ignaziocastagliuolo mlh1deficiencydownregulatestlr4expressioninsporadiccolorectalcancer
AT marcoscarpa mlh1deficiencydownregulatestlr4expressioninsporadiccolorectalcancer
_version_ 1721455492549574656